Ravidasvir

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.^[1]

Other namesPPI-668

ATC code

• J05AP13 (WHO)

CAS Number

• 1242087-93-9

PubChem CID

• 52918888

Quick facts Clinical data, Other names ...

Ravidasvir

Clinical data
Other names	PPI-668
ATC code	J05AP13 (WHO)
Identifiers
IUPAC name (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
CAS Number	1242087-93-9
PubChem CID	52918888
ChemSpider	31141686
UNII	AL3G001BI8
KEGG	D12744
ChEMBL	ChEMBL3121849
CompTox Dashboard (EPA)	DTXSID401335997
Chemical and physical data
Formula	C42H50N8O6
Molar mass	762.912 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1 Key:LCHMHYPWGWYXEL-ZYADHFCISA-N

Close

It is on the World Health Organization's List of Essential Medicines.^[2]

On December 11, 2024^[3] it was approved in Russia under the trade name Konesko for the treatment of chronic hepatitis C in adult patients (only in combination with sofosbuvir). In the pivotal clinical trial STORM-C-1, the majority of patients were infected with HCV genotypes 1 or 3. Data from this study in patients with HCV genotypes 2 and 6 are limited, and data on patients with genotypes 4 or 5 are not available.^[4]

Preliminary clinical trial results were announced in Nov 2015.^[5] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.^[6] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.^[7][8]